TNFRSF1B and cancer: Following the same notion, the combination of anti-TNFR2 (TY101) antibodies and anti-PD-1 (CD279) antibodies effectively reduced the number of TNFR2+T-regs and increased the ratio of CD8+ T cells in murine cancer models of CT26 and MC38 [304].